Senores Pharmaceuticals Ltd

- No new equity fundraising has been explicitly mentioned in the discussion. - Post-IPO proceeds, the company plans to utilize funds to streamline working capital, indicating reliance on existing raised funds rather than immediate new fundraising. - The company has planned a capex of INR 250 crores for FY 26, which is likely to be funded through internal accruals or existing financial resources. - There is no specific mention of fresh debt raising in the transcript. - Overall, the focus appears to be on organic growth, capacity expansion, and utilizing IPO funds rather than seeking new external debt or equity in the near term.

- Capex for FY26 is planned at INR 250 crores (Page 15). - Oral solids capacity expansion is ongoing with the 3rd line being installed and a 4th line planned to meet increased demand (Page 9). - New API facility (100-120 MTPA capacity) has commenced production; FDA trigger expected by Q2 2026 to support backward integration for US business (Pages 14-15). - The API facility primarily serves in-house needs with some external sales; it is positioned strategically rather than as a separate business vertical (Pages 14-15). - No increase in capex planned specifically for emerging markets; focus is on changing product mix to improve realization and EBITDA margins (Page 10). - A new greenfield site for semi-regulated and regulated market support in India is planned but land finalization is pending (Page 10). - Injectable capacity expansion planned in the US with capex scheduled by the end of the year (Page 9).

- The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. - Approximately 31 new ANDA product launches in the regulated market are expected in FY26. - Around 23 CDMO-CMO products are planned for commercialization in the current financial year. - Expansion in oral solids production capacity with two existing and two more lines being operational soon. - Emerging market product portfolio aims to grow to over 650 registered products by FY27. - Emerging market business margins expected to improve significantly, moving towards 15-16% EBITDA in 2 years. - PAT guidance for FY26 is a 100% increase compared to FY25, indicating strong profitability growth. - Growth driven by product mix changes, higher realizations, and strategic acquisitions. - Gradual improvement in working capital metrics aims to support volume growth. - No major capex planned; growth largely through product mix and capacity utilization.

- The company targets over 50% top-line growth in FY26 compared to FY25. - PAT (Profit After Tax) is expected to double (100% growth) in absolute terms in FY26. - EBITDA margin is expected to improve beyond the current 25% level and is considered sustainably 25% or higher. - Growth in PAT is primarily volume-driven, with a 100% improvement in PAT volume expected year-on-year. - Emerging market business EBITDA margin is currently ~7% with expectations of significant improvement next year. - The regulated market business and emerging market business are expected to witness aggressive ramp-up starting from Q1 in FY26, with more sizeable growth in the second half. - The company aims for continued expansion of its product portfolio and increased market penetration, supporting profitable growth and margin expansion.

- Senores Pharmaceuticals has a strong order book and good visibility in its CDMO-CMO segment. - The company continues to see steady traction and scaling up in the CDMO-CMO segment. - The portfolio now includes about 22 commercial products in CDMO-CMO with around 69 products in the pipeline at various stages. - Many of these pipeline products are expected to be commercialized in the current fiscal year. - The company has a solid pipeline with plans to launch 31 ANDA (Abbreviated New Drug Applications) products in the regulated market and 23 CDMO-CMO products in the current financial year. - There are ongoing multiple discussions to utilize current capacities until the US FDA trigger is received for the API facility. - Overall, the order pipeline and product launches provide good revenue visibility for the coming year.